Shenzhen Yaoxin Biotechnology

Shenzhen Pharmacin is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Shenzhen, China, with operations in Suzhou and New Haven, Connecticut. The company specializes in developing best-in-class therapeutics and high-end modified formulations via the 505(b)(2) regulatory pathway, focusing on oncology, immunology, allergy, and neurology. Utilizing its proprietary formulation platforms, such as the next-generation amorphous solid dispersion technology SprāSol®, Pharmacin overcomes bioavailability and solubility challenges for lipophilic and poorly soluble drugs. Its advanced pipeline includes clinical-stage candidates like HLK-1001 for breast cancer and HLK-0006, an oral epinephrine prodrug for anaphylaxis co-developed with Insignis Therapeutics.